{"url_path":"/sec/rajaf/10-k/2026/item-304","section_key":"item-304","section_title":"Item 304 (a)(1)(v) of Regulation S-K.","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1885680/0001213900-26-057774-index.html","accession_number":"0001213900-26-057774","cik":"0001885680","ticker":"RAJAF","issuer_name":"Cordyceps Sunshine Biotech Holdings Co., Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1885680/0001213900-26-057774-index.html","primary_entity_key":"0001885680","primary_entity_name":"Cordyceps Sunshine Biotech Holdings Co., Ltd."},"word_count":192,"has_tables":true,"body_markdown":"Item 304(a)(1)(v) of Regulation S-K.\n\n \n\nOn September 28, 2023, the Board of Directors\nof the Company approved and ratified the appointment of KCCW Accountancy Corp. as its new independent registered public accounting firm\nto audit the Company’s financial statements. During the two most recent fiscal years ended December 31, 2022 and 2021 and any subsequent\ninterim periods through the date hereof prior to the engagement of KCCW Accountancy Corp., neither the Company, nor someone on its behalf,\nhas consulted KCCW Accountancy Corp. regarding: (i) either: the application of accounting principles to a specified transaction, either\ncompleted or proposed; or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and\neither a written report was provided to the Company or oral advice was provided that the new independent registered public accounting\nfirm concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting\nissue; or (ii) any matter that was either the subject of a disagreement as defined in paragraph 304(a)(1)(iv) of Regulation S-K or a reportable\nevent as described in paragraph 304(a)(1)(v) of Regulation S-K.\n\n \n\n46"}